Alfredo Ramirez

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9570949/publications.pdf

Version: 2024-02-01

192 papers	22,265 citations	28272 55 h-index	11052 137 g-index
221 all docs	221 docs citations	221 times ranked	30762 citing authors

#	Article	IF	Citations
1	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	21.4	3,741
2	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates Aî², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
3	Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. New England Journal of Medicine, 2012, 367, 319-328.	27.0	1,426
4	Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nature Genetics, 2018, 50, 381-389.	21.4	1,332
5	Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nature Genetics, 2006, 38, 1184-1191.	21.4	1,046
6	nâ€“3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia. New England Journal of Medicine, 2012, 367, 309-318.	27.0	810
7	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
8	New insights into the genetic etiology of Alzheimerâ€™s disease and related dementias. Nature Genetics, 2022, 54, 412-436.	21.4	700
9	Mapping the human genetic architecture of COVID-19. Nature, 2021, 600, 472-477.	27.8	640
10	TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Science Translational Medicine, 2014, 6, 243ra86.	12.4	600
11	Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. Nature Communications, 2018, 9, 2098.	12.8	484
12	Mutation of CDH23, encoding a new member of the cadherin gene family, causes Usher syndrome type 1D. Nature Genetics, 2001, 27, 108-112.	21.4	442
13	G proteinâ€“coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nature Genetics, 2008, 40, 329-334.	21.4	385
14	Common polygenic variation enhances risk prediction for Alzheimerâ€™s disease. Brain, 2015, 138, 3673-3684.	7.6	359
15	Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 9611-9616.	7.1	309
16	Mutations in CLCN2 encoding a voltage-gated chloride channel are associated with idiopathic generalized epilepsies. Nature Genetics, 2003, 33, 527-532.	21.4	297
17	A novel Alzheimer disease locus located near the gene encoding tau protein. Molecular Psychiatry, 2016, 21, 108-117.	7.9	260
18	A Panâ€<scp>E</scp>uropean Study of theC9orf72Repeat Associated with<scp>FTLD</scp>: Geographic Prevalence, Genomic Instability, and Intermediate Repeats. Human Mutation, 2013, 34, 363-373.	2.5	247

#	Article	IF	Citations
19	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	2.6	215
20	Mutations in CAV3 cause mechanical hyperirritability of skeletal muscle in rippling muscle disease. Nature Genetics, 2001, 28, 218-219.	21.4	206
21	Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 658-671.	0.8	173
22	Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	2.3	170
23	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661.	2.5	155
24	Associations between Potentially Modifiable Risk Factors and Alzheimer Disease: A Mendelian Randomization Study. PLoS Medicine, 2015, 12, e1001841.	8.4	153
25	Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies. Alzheimer's and Dementia, 2018, 14, 707-722.	0.8	143
26	Mutant Parkin Impairs Mitochondrial Function and Morphology in Human Fibroblasts. PLoS ONE, 2010, 5, e12962.	2.5	140
27	Common variants in Alzheimerâ€™s disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	12.8	140
28	Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimerâ€™s disease (DELCODE). Alzheimer's Research and Therapy, 2018, 10, 15.	6.2	131
29	Whispering dysphonia (DYT4 dystonia) is caused by a mutation in the TUBB4 gene. Annals of Neurology, 2013, 73, 537-545.	5.3	128
30	Effect of endogenous mutant and wild-type PINK1 on Parkin in fibroblasts from Parkinson disease patients. Human Molecular Genetics, 2010, 19, 3124-3137.	2.9	117
31	Neuroimmune Connections in Aging and Neurodegenerative Diseases. Trends in Immunology, 2020, 41, 300-312.	6.8	111
32	ATP13A2 mutations impair mitochondrial function in fibroblasts from patients with Kufor-Rakeb syndrome. Neurobiology of Aging, 2012, 33, 1843.e1-1843.e7.	3.1	106
33	Genome-wide significant risk factors for Alzheimerâ€™s disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment. Molecular Psychiatry, 2017, 22, 153-160.	7.9	102
34	Follow-up of loci from the International Genomics of Alzheimerâ€™s Disease Project identifies TRIP4 as a novel susceptibility gene. Translational Psychiatry, 2014, 4, e358-e358.	4.8	98
35	Clinical spectrum of Kuforâ€Rakeb syndrome in the Chilean kindred with ATP13A2 mutations. Movement Disorders, 2010, 25, 1929-1937.	3.9	93
36	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. Acta Neuropathologica, 2014, 128, 397-410.	7.7	93

#	Article	IF	Citations
37	Quantitative Interaction Proteomics of Neurodegenerative Disease Proteins. Cell Reports, 2015, 11, 1134-1146.	6.4	88
38	Alzheimerâ€™s disease-associated (hydroxy)methylomic changes in the brain and blood. Clinical Epigenetics, 2019, 11, 164.	4.1	88
39	TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Human Mutation, 2017, 38, 297-309.	2.5	87
40	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimerâ€™s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica, 2019, 138, 237-250.	7.7	87
41	Hypomorphic mutations in POLR3A are a frequent cause of sporadic and recessive spastic ataxia. Brain, 2017, 140, 1561-1578.	7.6	85
42	Cloning and Characterization of SLC26A6, a Novel Member of the Solute Carrier 26 Gene Family. Genomics, 2001, 72, 43-50.	2.9	84
43	Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimerâ€™s disease. Brain, 2018, 141, 1186-1200.	7.6	83
44	Frequency of the D620N Mutation in VPS35 in Parkinson Disease. Archives of Neurology, 2012, 69, 1360.	4.5	76
45	Genetic Predisposition to Increased Blood Cholesterol and Triglyceride Lipid Levels and Risk of Alzheimer Disease: A Mendelian Randomization Analysis. PLoS Medicine, 2014, 11, e1001713.	8.4	75
46	Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer. JAMA Oncology, 2017, 3, 1245.	7.1	74
47	Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study. Alzheimer's Research and Therapy, 2019, 11, 66.	6.2	74
48	Recessively Inherited Parkinsonism. Archives of Neurology, 2010, 67, 1357-63.	4.5	73
49	Rare missense variants inATP1A2 in families with clustering of common forms of migraine. Human Mutation, 2005, 26, 315-321.	2.5	72
50	Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age. Neurology, 2021, 96, .	1.1	72
51	Identification of a novel mutation in the coding region of the grey-lethal geneOSTM1in human malignant infantile osteopetrosis. Human Mutation, 2004, 23, 471-476.	2.5	69
52	Lysosomal dysfunction in Parkinson disease. Autophagy, 2012, 8, 1389-1391.	9.1	69
53	Advanced glycation end products and protein carbonyl levels in plasma reveal sex-specific differences in Parkinson's and Alzheimer's disease. Redox Biology, 2020, 34, 101546.	9.0	66
54	ATP13A2 variants in earlyâ€onset Parkinson's disease patients and controls. Movement Disorders, 2009, 24, 2104-2111.	3.9	62

#	Article	IF	Citations
55	The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimerâ€™s disease. Molecular Psychiatry, 2021, 26, 614-628.	7.9	61
56	Splice variants of a ClC-2 chloride channel with differing functional characteristics. American Journal of Physiology - Cell Physiology, 2000, 279, C1198-C1210.	4.6	58
57	PLD3 in non-familial Alzheimer's disease. Nature, 2015, 520, E3-E5.	27.8	58
58	Minor neuropsychological deficits in patients with subjective cognitive decline. Neurology, 2020, 95, e1134-e1143.	1.1	58
59	Shared genetic contribution to ischemic stroke and Alzheimer's disease. Annals of Neurology, 2016, 79, 739-747.	5.3	56
60	Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE). Diabetes Care, 2016, 39, 709-716.	8.6	55
61	Impaired sense of smell and color discrimination in monogenic and idiopathic Parkinson's disease. Movement Disorders, 2010, 25, 2665-2669.	3.9	53
62	Nonmotor Symptoms in Genetic Parkinson Disease. Archives of Neurology, 2010, 67, 670-6.	4.5	53
63	Glucocerebrosidase mutations in a <scp>S</scp>erbian <scp>P</scp>arkinson's disease population. European Journal of Neurology, 2013, 20, 402-405.	3.3	53
64	GBA and APOE Îµ4 associate with sporadic dementia with Lewy bodies in European genome wide association study. Scientific Reports, 2019, 9, 7013.	3.3	53
65	Elevated HbA1c is Associated with Increased Risk of Incident Dementia in Primary Care Patients. Journal of Alzheimer's Disease, 2015, 44, 1203-1212.	2.6	52
66	Worldwide surveillance of self-reported sitting time: a scoping review. International Journal of Behavioral Nutrition and Physical Activity, 2020, 17, 111.	4.6	52
67	CLCN2 variants in idiopathic generalized epilepsy. Nature Genetics, 2009, 41, 954-955.	21.4	50
68	Neurokinin3 receptor as a target to predict and improve learning and memory in the aged organism. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 15097-15102.	7.1	50
69	Alzheimer's disease risk variants modulate endophenotypes in mild cognitive impairment. Alzheimer's and Dementia, 2016, 12, 872-881.	0.8	50
70	Genetic interaction of PICALM and APOE is associated with brain atrophy and cognitive impairment in Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, S269-76.	0.8	47
71	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. Human Molecular Genetics, 2022, 31, 3945-3966.	2.9	46
72	SUCLG2 identified as both a determinator of CSF AÎ²1â€“42 levels and an attenuator of cognitive decline in Alzheimer's disease. Human Molecular Genetics, 2014, 23, 6644-6658.	2.9	45

#	Article	IF	Citations
73	Structural imaging in the presymptomatic stage of genetically determined parkinsonism. Neurobiology of Disease, 2010, 39, 402-408.	4.4	43
74	The rare TREM2 R47H variant exerts only a modest effect on Alzheimer disease risk. Neurology, 2014, 83, 1353-1358.	1.1	40
75	Recessive dystonia-ataxia syndrome in a Turkish family caused by a COX20 (FAM36A) mutation. Journal of Neurology, 2014, 261, 207-212.	3.6	40
76	PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. Acta Neuropathologica, 2020, 139, 1025-1044.	7.7	40
77	Homozygous THAP1 mutations as cause of earlyâ€onset generalized dystonia. Movement Disorders, 2011, 26, 858-861.	3.9	39
78	Caspase-8, association with Alzheimerâ€™s Disease and functional analysis of rare variants. PLoS ONE, 2017, 12, e0185777.	2.5	38
79	Disentangling the biological pathways involved in early features of Alzheimer's disease in the Rotterdam Study. , 2018, 14, 848-857.		36
80	Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes. Neurobiology of Aging, 2014, 35, 2657.e13-2657.e19.	3.1	34
81	MAPT H1 Haplotype is Associated with Late-Onset Alzheimerâ€™s Disease Risk in APOE É›4 Noncarriers: Results from the Dementia Genetics Spanish Consortium. Journal of Alzheimer's Disease, 2015, 49, 343-352.	2.6	32
82	Transethnic meta-analysis of rare coding variants in PLCG2, ABI3, and TREM2 supports their general contribution to Alzheimerâ€™s disease. Translational Psychiatry, 2019, 9, 55.	4.8	32
83	Dietary patterns are related to cognitive functioning in elderly enriched with individuals at increased risk for Alzheimerâ€™s disease. European Journal of Nutrition, 2021, 60, 849-860.	3.9	31
84	Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. JAMA Neurology, 2022, 79, 652.	9.0	31
85	Generation of a set of isogenic, gene-edited iPSC lines homozygous for all main APOE variants and an APOE knock-out line. Stem Cell Research, 2019, 34, 101349.	0.7	29
86	Multiple isoforms of the tumor protein p73 are expressed in the adult human telencephalon and choroid plexus and present in the cerebrospinal fluid. European Journal of Neuroscience, 2006, 23, 2109-2118.	2.6	28
87	Characterization of ADAMTS14, a novel member of the ADAMTS metalloproteinase family. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2001, 1522, 221-225.	2.4	27
88	A mutation in the signal sequence ofLRP5in a family with an osteoporosis-pseudoglioma syndrome (OPPG)-like phenotype indicates a novel disease mechanism for trinucleotide repeats. Human Mutation, 2009, 30, 641-648.	2.5	27
89	DNA Methylation of the TNF-Î± Promoter Region in Peripheral Blood Monocytes and the Cortex of Human Alzheimer's Disease Patients. Dementia and Geriatric Cognitive Disorders, 2014, 38, 10-15.	1.5	27
90	The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease. Neurobiology of Aging, 2015, 36, 1605.e13-1605.e20.	3.1	27

#	Article	IF	Citations
91	Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimerâ€™s disease. Neuron, 2022, 110, 1009-1022.e4.	8.1	27
92	The SCDâ€Well randomized controlled trial: Effects of a mindfulnessâ€based intervention versus health education on mental health in patients with subjective cognitive decline (SCD). Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 737-745.	3.7	26
93	CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 782-790.	2.4	26
94	Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers. Alzheimer's and Dementia, 2023, 19, 487-497.	0.8	25
95	Gene-based analysis in HRC imputed genome wide association data identifies three novel genes for Alzheimerâ€™s disease. PLoS ONE, 2019, 14, e0218111.	2.5	23
96	Apolipoprotein E Îµ4 does not affect cognitive performance in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2016, 29, 112-116.	2.2	22
97	Genome-wide significant risk factors on chromosome 19 and the APOE locus. Oncotarget, 2018, 9, 24590-24600.	1.8	22
98	Prevalence of Anxiety Symptoms and Their Association With Loss Experience in a Large Cohort Sample of the Oldest-Old. Results of the AgeCoDe/AgeQualiDe Study. Frontiers in Psychiatry, 2019, 10, 285.	2.6	22
99	Association of Parkinson disease to PARK16 in a Chilean sample. Parkinsonism and Related Disorders, 2011, 17, 70-71.	2.2	19
100	Variants in the 3â€²UTR of SNCA do not affect miRNA-433 binding and alpha-synuclein expression. European Journal of Human Genetics, 2012, 20, 1265-1269.	2.8	19
101	Low High-Density Lipoprotein and Risk of Myocardial Infarction. Clinical Medicine Insights: Cardiology, 2015, 9, CMC.S26624.	1.8	19
102	Eicosapentaenoic Acid Is Associated with Decreased Incidence of Alzheimerâ€™s Dementia in the Oldest Old. Nutrients, 2021, 13, 461.	4.1	18
103	TREM2 rare variant p.R47H is not associated with Parkinson's disease. Parkinsonism and Related Disorders, 2016, 23, 109-111.	2.2	17
104	CDH6 and HAGH protein levels in plasma associate with Alzheimerâ€™s disease in APOE Îµ4 carriers. Scientific Reports, 2020, 10, 8233.	3.3	17
105	Hypermethylation of the oxytocin receptor gene (OXTR) in obsessive-compulsive disorder: further evidence for a biomarker of disease and treatment response. Epigenetics, 2022, 17, 642-652.	2.7	17
106	Amyloid pathology but notAPOEÎµ4 status is permissive for tau-related hippocampal dysfunction. Brain, 2022, 145, 1473-1485.	7.6	17
107	Matrix metalloproteinase 10 is linked to the risk of progression to dementia of the Alzheimerâ€™s type. Brain, 2022, 145, 2507-2517.	7.6	16
108	Alzheimerâ€™s Disease Plasma Biomarkers Distinguish Clinical Diagnostic Groups in Memory Clinic Patients. Dementia and Geriatric Cognitive Disorders, 2022, 51, 182-192.	1.5	16

#	Article	IF	Citations
109	Multicenter Tract-Based Analysis of Microstructural Lesions within the Alzheimerâ€™s Disease Spectrum: Association with Amyloid Pathology and Diagnostic Usefulness. Journal of Alzheimer's Disease, 2019, 72, 455-465.	2.6	15
110	Multiomics integrative analysis identifies APOE allele-specific blood biomarkers associated to Alzheimerâ€™s disease etiopathogenesis. Aging, 2021, 13, 9277-9329.	3.1	15
111	Eye movement disorders in ATP13A2 mutation carriers (PARK9). Movement Disorders, 2010, 25, 2687-2689.	3.9	14
112	Methylomic profiling in trisomy 21 identifies cognition- and Alzheimerâ€™s disease-related dysregulation. Clinical Epigenetics, 2019, 11, 195.	4.1	14
113	Correlates of hospitalization among the oldest old: results of the AgeCoDeâ€“AgeQualiDe prospective cohort study. Aging Clinical and Experimental Research, 2020, 32, 1295-1301.	2.9	14
114	Abnormal Regional and Global Connectivity Measures in Subjective Cognitive Decline Depending on Cerebral Amyloid Status. Journal of Alzheimer's Disease, 2021, 79, 493-509.	2.6	14
115	Genetic association study of the Pâ€type ATPase ATP13A2 in lateâ€onset Parkinson's disease. Movement Disorders, 2009, 24, 429-433.	3.9	13
116	The polygenic risk for obsessiveâ€compulsive disorder is associated with the personality trait harm avoidance. Acta Psychiatrica Scandinavica, 2020, 142, 326-336.	4.5	13
117	Linking Protective GAB2 Variants, Increased Cortical GAB2 Expression and Decreased Alzheimerâ€™s Disease Pathology. PLoS ONE, 2013, 8, e64802.	2.5	13
118	Genetic estimators of DNA methylation provide insights into the molecular basis of polygenic traits. Translational Psychiatry, 2018, 8, 31.	4.8	12
119	Exploring Genetic Associations of Alzheimerâ€™s Disease Loci With Mild Cognitive Impairment Neurocognitive Endophenotypes. Frontiers in Aging Neuroscience, 2018, 10, 340.	3.4	12
120	Association of lysophosphatidic acids with cerebrospinal fluid biomarkers and progression to Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 124.	6.2	12
121	Resting-State Network Alterations Differ between Alzheimerâ€™s Disease Atrophy Subtypes. Cerebral Cortex, 2021, 31, 4901-4915.	2.9	12
122	Association of Cholinergic Basal Forebrain Volume and Functional Connectivity with Markers of Inflammatory Response in the Alzheimerâ€™s Disease Spectrum. Journal of Alzheimer's Disease, 2022, 85, 1267-1282.	2.6	12
123	Cognitive behavioural therapy for the treatment of late life depression: study protocol of a multicentre, randomized, observer-blinded, controlled trial (CBTlate). BMC Psychiatry, 2019, 19, 423.	2.6	11
124	The association between genomeâ€wide polymorphisms and chronic postoperative pain: a prospective observational study. Anaesthesia, 2020, 75, e111-e120.	3.8	11
125	Reply: POLR3A variants in hereditary spastic paraplegia and ataxia. Brain, 2018, 141, e2-e2.	7.6	10
126	Measuring Psychological Mechanisms in Meditation Practice: Using a Phenomenologically Grounded Classification System to Develop Theory-Based Composite Scores. Mindfulness, 2022, 13, 600.	2.8	9

#	Article	IF	Citations
127	Novel genetic matching methods for handling population stratification in genome-wide association studies. BMC Bioinformatics, 2015, 16, 84.	2.6	8
128	P3â€591: A GERMAN VERSION OF THE LIFETIME OF EXPERIENCES QUESTIONNAIRE (LEQ) TO MEASURE COGNITIVE RESERVE: VALIDATION RESULTS FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P1352.	0.8	8
129	Polygenic risk for obsessive-compulsive disorder (OCD) predicts brain response during working memory task in OCD, unaffected relatives, and healthy controls. Scientific Reports, 2021, 11, 18914.	3.3	8
130	Motor pathway excitability in ATP13A2 mutation carriers: A transcranial magnetic stimulation study. Parkinsonism and Related Disorders, 2012, 18, 590-594.	2.2	6
131	Exome sequencing identifies three novel ADâ€associated genes. Alzheimer's and Dementia, 2020, 16, e041592.	0.8	6
132	Association of the Polygenic Risk Score With the Probability of Prodromal Parkinsonâ€™s Disease in Older Adults. Frontiers in Molecular Neuroscience, 2021, 14, 739571.	2.9	6
133	Clinical and Genetic Analysis of a Chilean Family with Early-Onset Autosomal Dominant Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 21, 757-761.	2.6	5
134	No association of the variant rs11887120 in DNMT3A with cognitive decline in individuals with mild cognitive impairment. Epigenomics, 2016, 8, 593-598.	2.1	5
135	Blood-derived integration-free iPS cell line UKBi011-A from a diagnosed male Alzheimer's disease patient with APOE É›4/É›4 genotype. Stem Cell Research, 2018, 29, 250-253.	0.7	5
136	Does transpersonal trust moderate the association between chronic conditions and general practitioner visits in the oldest old? Results of the AgeCoDe and AgeQualiDe study. Geriatrics and Gerontology International, 2019, 19, 705-710.	1.5	5
137	Challenges at the APOE locus: a robust quality control approach for accurate APOE genotyping. Alzheimer's Research and Therapy, 2022, 14, 22.	6.2	5
138	Relevance of Subjective Cognitive Decline in Older Adults with a First-Degree Family History of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 87, 545-555.	2.6	5
139	Reply: Biallelic POLR3A variants confirmed as a frequent cause of hereditary ataxia and spastic paraparesis. Brain, 2019, 142, e13-e13.	7.6	4
140	A rare heterozygous TREM2 coding variant identified in familial clustering of dementia affects an intrinsically disordered protein region and function of TREM2. Human Mutation, 2020, 41, 169-181.	2.5	4
141	Intermediate phenotype of ATP13A2 mutation in two Chilean siblings: Towards a continuum between parkinsonism and hereditary spastic paraplegia. Parkinsonism and Related Disorders, 2020, 81, 45-47.	2.2	4
142	Cognitive profiles of patients with mild cognitive impairment due to Alzheimer's versus Parkinson's disease defined using a base rate approach: Implications for neuropsychological assessments. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12223.	2.4	4
143	APOE É›4 Is Associated with Postprandial Inflammation in Older Adults with Metabolic Syndrome Traits. Nutrients, 2021, 13, 3924.	4.1	4
144	An unusual neurological syndrome of crawling gait, dystonia, pyramidal signs, and limited speech. Movement Disorders, 2011, 26, 2279-2283.	3.9	3

#	Article	IF	Citations
145	Rare Variant Testing of Imputed Data: An Analysis Pipeline Typified. Human Heredity, 2014, 78, 164-178.	0.8	3
146	Association of a CAMK2A genetic variant with logical memory performance and hippocampal volume in the elderly. Brain Research Bulletin, 2020, 161, 13-20.	3.0	3
147	SEARCHING FOR THE HOLY GRAIL WILL NEED BIOMARKERS. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-3.	2.7	3
148	A One-Degree-of-Freedom Test for Supra-Multiplicativity of SNP Effects. PLoS ONE, 2013, 8, e78038.	2.5	2
149	P2-049: Functional characterization of a novel TREM2 coding variant linked to familial Alzheimer's disease. , 2015, 11, P500-P500.		2
150	[P3â€“528]: PROSPECTIVE ASSOCIATIONS BETWEEN VITAMINS, METABOLITES, AND OVERALL DEMENTIA IN THE OLDESTâ€OLD. Alzheimer's and Dementia, 2017, 13, P1180.	0.8	2
151	Genetically elevated highâ€density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 595-598.	2.4	2
152	APOE and sexâ€stratified genomeâ€wide metaâ€analyses of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e040779.	0.8	2
153	Association between 9p21-23 Locus and Frailty in a Community-Dwelling Greek Population: Results from the Hellenic Longitudinal Investigation of Ageing and Diet. journal of prevention of Alzheimer's disease, The, 2022, 9, 1-9.	2.7	2
154	Uncovering the Contribution of Moderate-Penetrance Susceptibility Genes to Breast Cancer by Whole-Exome Sequencing and Targeted Enrichment Sequencing of Candidate Genes in Women of European Ancestry. Cancers, 2022, 14, 3363.	3.7	2
155	O4-04-04: TOWARD FINE MAPPING AND FUNCTIONAL CHARACTERIZATION OF GENOME-WIDE ASSOCIATION STUDY-IDENTIFIED LOCUS RS74615166 (TRIP4) FOR ALZHEIMER'S DISEASE. , 2014, 10, P257-P258.		1
156	3 .Neuropathologie und molekulare Mechanismen. , 2018, , 35-122.		1
157	T40. Alzheimerâ€™s Disease DNA (Hydroxy)Methylome in the Brain and Blood: Evidence for OXT Methylation as a Preclinical Marker. Biological Psychiatry, 2019, 85, S144.	1.3	1
158	Intrathecal antibodies against herpes simplex virus are associated with tau pathology in humans with Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e041938.	0.8	1
159	Genomeâ€wide metaâ€analysis of lateâ€onset Alzheimerâ€™s disease using rare variant imputation in 65,602 subjects identifies risk loci with roles in memory, neurodevelopment, and cardiometabolic traits: The international genomics of Alzheimerâ€™s project (IGAP). Alzheimer's and Dementia, 2020, 16, e044193.	0.8	1
160	SORL1 â€variant carriers in ADESâ€ADSP: A higher level of variant pathogenicity associates with earlier age at onset of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e044492.	0.8	1
161	Generation of a set of isogenic iPSC lines carrying all APOE genetic variants (Æ2/Æ3/Æ4) and knock-out for the study of APOE biology in health and disease. Stem Cell Research, 2021, 52, 102180.	0.7	1
162	TH56. HYPERMETHYLATION OF THE OXYTOCIN RECEPTOR GENE IN OBSESSIVE-COMPULSIVE DISORDER: FURTHER EVIDENCE FOR A BIOMARKER OF DISEASE AND TREATMENT RESPONSE. European Neuropsychopharmacology, 2021, 51, e224.	0.7	1

#	Article	IF	Citations
163	Exome sequencing identifies rare damaging variants in the ATB8B4 and ABCA1 genes as novel risk factors for Alzheimer's disease.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e055982.	0.8	1
164	MigraÃ±a con aura: Una mirada molecular a un problema hereditario. Revista Chilena De Neuro-Psiquiatria, 2006, 44, 98.	0.1	0
165	Populationâ€<scp>B</scp>ased <scp>G</scp>enetic <scp>S</scp>tudies: <scp>T</scp>he <scp>S</scp>earch for <scp>C</scp>ausative <scp>V</scp>ariants in <scp>P</scp>arkinson's <scp>D</scp>isease. Movement Disorders, 2015, 30, 1297-1300.	3.9	0
166	[P2â€“550]: CONNECTIVITY OF THE LEFT FRONTAL CORTEX ATTENUATES DETRIMENTAL EFFECTS OF CSFâ€TAU ON MEMORY IN PRECLINICAL AND CLINICAL ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P854.	0.8	0
167	[P3â€“164]: FUNCTIONAL CHARACTERIZATION OF A RARE GENETIC VARIANT IN PHOSPHOLIPASE CÎ³2 WHICH IS ASSOCIATED WITH A BENEFICIAL EFFECT ON THE PROGRESSION OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P997.	0.8	0
168	[P1â€“139]: PATHWAYâ€SPECIFIC GENETIC RISK SCORE ASSOCIATED WITH ALZHEIMER's DISEASE AND WHITE MATTER LESIONS IN COGNITIVELY NORMAL SUBJECTS. Alzheimer's and Dementia, 2017, 13, P295.	0.8	0
169	[P1â€“340]: CASE REPORT: HETEROZYGOUS APP A713T MUTATION CARRIER WITH INFLAMMATORY AMYLOID ANGIOPATHY AND FAMILY HISTORY OF AD: FIRST CASE IN ARGENTINA. Alzheimer's and Dementia, 2017, 13, P386.	0.8	0
170	[P1â€“554]: OPTIMAL HARMONIZATION OF COGNITIVE MEASURES ENHANCES THE DETECTION OF GENETIC EFFECTS ON ALZHEIMER's DISEASE PROGRESSION: A COMPARISON OF SIX STATISTICAL APPROACHES IN 1796 MCI PATIENTS FROM THREE COHORTS. Alzheimer's and Dementia, 2017, 13, P506.	0.8	0
171	P1â€028: OCCUPATIONAL COGNITIVE REQUIREMENTS ARE AN IMPORTANT PROXY MEASURE OF COGNITIVE RESERVE: EVIDENCE FROM THE AGECODE AND DELCODE STUDIES. Alzheimer's and Dementia, 2018, 14, P276.	0.8	0
172	O5â€04â€01: A RARE GENETIC VARIANT IN THE PLCG2 GENE IS ASSOCIATED WITH A REDUCED RISK OF ALL MAJOR TYPES OF DEMENTIA AND AN INCREASED RISK TO REACH AN EXTREMELY OLD AGE. Alzheimer's and Dementia, 2018, 14, P1648.	0.8	0
173	P1â€140: A GENERIC LATENT VARIABLE APPROACH FOR MEASURING COGNITIVE RESERVE: PHENOTYPE VALIDATION AND GENETIC ASSOCIATION RESULTS. Alzheimer's and Dementia, 2018, 14, P328.	0.8	0
174	P3â€122: APOEâ€Îµ4 MODULATES LEVELS OF OMEGAâ€3 AND OMEGAâ€6 FATTY ACIDS IN ALZHEIMER'S DISEASE DEMENTIA. Alzheimer's and Dementia, 2018, 14, P1114.	0.8	0
175	P1â€298: CEREBROSPINAL FLUID AND PLASMA LEVELS OF LYSOPHOSPHATIDIC ACIDS (LPAS) ASSOCIATE WITH CEREBROSPINAL FLUID AÎ²â€42 AND Pâ€TAU. Alzheimer's and Dementia, 2018, 14, P403.	0.8	0
176	P3â€131: LOOKING FOR THERAPEUTIC ENTRY POINTS FOR ALZHEIMER'S DISEASE: LESSONS LEARNED FROM AGNOSTIC TRANSâ€COâ€REGULATORY NETWORK ANALYSES OF APOE, TREM2, PLCG2 AND ABI3 LOCI. Alzheimer's and Dementia, 2018, 14, P1117.	0.8	0
177	P2â€431: RELATIONSHIP BETWEEN LOCAL RESTING STATE ACTIVITY, Î²â€AMYLOID DEPOSITION AND MEMORY PERFORMANCE IN THE DZNE: LONGITUDINAL COGNITIVE IMPAIRMENT AND DEMENTIA STUDY (DELCODE). Alzheimer's and Dementia, 2018, 14, P877.	0.8	0
178	P1â€159: RARE VARIANTS IN PLCG2, ABI3, AND TREM2 GENES ARE ASSOCIATED WITH ALZHEIMER'S DISEASE IN AN ARGENTINIAN SAMPLE: IS IT A EUROPEAN HERITAGE?. Alzheimer's and Dementia, 2018, 14, P337.	0.8	0
179	M62 THE POLYGENIC RISK FOR OBSESSIVE-COMPULSIVE DISORDER IS ASSOCIATED WITH HARM AVOIDANCE IN A SAMPLE OF OCD PATIENTS, UNAFFECTED RELATIVES AND CONTROLS. European Neuropsychopharmacology, 2019, 29, S199-S200.	0.7	0
180	THE APOE-Îµ4 ALLELE AND AGE SYNERGISTICALLY DRIVE DISEASE PROGRESSION IN ALZHEIMERâ€™S DISEASE. Innovation in Aging, 2019, 3, S943-S943.	0.1	0

#	Article	IF	Citations
181	Potential epigenetic pathways linking high mental work demands to dementia risk. Alzheimer's and Dementia, 2020, 16, e039663.	0.8	0
182	Can OMICS data help us to understand the mechanisms of APOE?. Alzheimer's and Dementia, 2020, 16, e040276.	0.8	0
183	Crossâ€omics studies of the role of apolipoprotein E in Alzheimerâ€™s disease and dementia: Searching common pathways in patients, populations and cellular models. Alzheimer's and Dementia, 2020, 16, e040282.	0.8	0
184	Development of a fast and versatile method for genomeâ€wide association studies of longitudinal data. Alzheimer's and Dementia, 2020, 16, e042441.	0.8	0
185	Lifestyle differences modulate the effects of cognitive reserve on functional connectivity. Alzheimer's and Dementia, 2020, 16, e042947.	0.8	0
186	Hippocampal volumetric variability is associated with memory in subjective cognitive decline. Alzheimer's and Dementia, 2020, 16, e043527.	0.8	0
187	PLCG2 Protective Variant p.P522R Modulates Tau Pathology and Disease Progression in Patients with Mild Cognitive Impairment. SSRN Electronic Journal, 0, , .	0.4	0
188	Amyloid-related changes of basal forebrain volume and precuneus functional connectivity in Subjective Cognitive Decline patients. , 2020, 59, .		0
189	Individualized MRâ€based prediction of cognitive performance in subjects at risk of dementia. Alzheimer's and Dementia, 2021, 17, .	0.8	0
190	Plasma biomarkers distinguish clinical diagnostic groups in memory clinic patients. Alzheimer's and Dementia, 2021, 17, .	0.8	0
191	In vivo amyloid staging in individuals with subjective cognitive decline in DELCODE Study. Alzheimer's and Dementia, 2021, 17, .	0.8	0
192	Vascular burden and genetic risk in association with cognitive performance and dementia in a population-based study. Cerebral Circulation - Cognition and Behavior, 2022, 3, 100145.	0.9	0